Table 2. Combined summary data for AMIGO trials with exenatide.

Baseline HbA1c was 8.6% in the first AMIGO trial [43], 8.2% in AMIGO 2 [44] and 8.5% in AMIGO 3 [45]. SU: sulfonylurea. Exen: exenatide. MET: metformin. FPG: fasting plasma glucose. BID: twice daily. 1 Fraction of patients (in %) with HbA1c ≤ 7% at the end of the study. 2 Fraction of patients with adverse effects (in %). 3 Mild to moderate hypoglycemia.